Prof. Marianne Verhaar

Verhaar ZW

Date of Birth: 30 July 1967; Position Title: Professor of Experimental Nephrology; Education/Training: MD, Erasmus University Rotterdam (1992); PhD, Cum Laude, Utrecht University (1999); Clinical Specialization: Internal Medicine (2000), Vascular Medicine (2003), Nephrology (2012).

Positions and Honors

  1. Positions and Employment: Chair department of Nephrology and Hypertension, UMC Utrecht (2014- ); professor of Experimental Nephrology, dept Nephrology and Hypertension, UMC Utrecht (2009- ); staff-member Vascular Medicine, UMC Utrecht (2000-2009).
  2. Other Experience and Professional Memberships: visiting professor Experimental Nephrology, New York Medical College, USA (2009); ‘Kernteam’ member focus area Regenerative Medicine UMC Utrecht (2011- ); course director Cardiovascular RM PhD programme, UMC Utrecht (2009- ); ZonMw Scientific Board Translational Research, ZonMw Scientific Board Innovational Research Incentives Veni, Scientific Board European Commission – evaluation of EU research proposals in the area of Regenerative MedicineSteering Committee Utrecht Cardiovascular Cohort. promotor/copromotor of 15 completed PhD theses, supervisor of 15 ongoing PhD-projects.
  3. Honors and Awards: Dutch Hypertension Society, presentation award (1997); ‘Jaarprijs’ Vascular Biology, Dutch Society of Cardiology (1998); PhD Cum Laude (1999); VENI Career Development Award, (ZonMw/NWO)(2002); Steyn-Parvé II Award for Research Talent (Senior level, UMC Utrecht)(2006); VIDI Career Development Award, (ZonMw/NWO)(2008); Aspasia Career Development Award (ZonMw/NWO)(2009); Dirkzwager-Assink prijs (2010)

Peer-reviewed publications

110 publications, h-index 30

  1. Teraa M, Fledderus JO, Rozbeh RI, Leguit RJ, Verhaar MC. Bone marrow microvascular and neuropathic alterations in critical limb ischemia patients. Circulation Research 2014; 114(2):311-4. [IF 11.861]
  2. van Balkom BWM, de Jong OG, Smits M, Brummelman J, den Ouden K, de Bree PM, van Eijndhoven MAJ, Pegtel DM, Stoorvogel W, Würdinger W, Verhaar MC. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. Blood. 2013; 121(19): 3997-4006. [IF 9.060]
  3. van Balkom BWM, Pisitkun T, Verhaar MC, Knepper MA. Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. Kidney Int. 2011;80:1138-45. [IF 7.916]
  4. Gremmels H, Fledderus JO, van Balkom BWM, Verhaar MC. Transcriptome analysis as a tool in EPC biology. Antioxid Redox Signal. 2011;15:1029-42. IF 7.189]
  5. Westerweel PE, Visseren FL, Hajer GR, Olijhoek JK, Hoefer IE, de Bree P, Rafii S, Doevendans PA, Verhaar MC. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy versus simvastatin/ ezetimibe combination therapy. Eur Heart Journal 29:2808-17 (2008). [IF 14.097]
  6. Westerweel PE, Verhaar MC. Directing myogenic mesenchymal stem cell differentiation. Circulation Res 103:560-1 (2008). [IF 11.861]
  7. Westerweel PE, Luijten RKMAC, Koomans HA, Derksen RHWM, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum. 56:1384-1396 (2007).[IF 8.4]
  8. Westerweel PE, Luijten RKMAC, Hoefer IE, Koomans HA, Derksen RHWM, Verhaar MC. Hematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis 66:865-70 (2007). [IF 9.111].
  9. Rookmaaker MB, Vergeer M, van Zonneveld AJ, Rabelink TJ, Verhaar MC. Endothelial progenitor cells: mainly derived from the monocyte/macrophage-containing CD34- mononuclear cell population and only in part from the hematopoietic stem cell-containing CD34+ mononuclear cell population. Circulation 108:e150 (2003) [IF 15.202]
  10. Rookmaaker MB, Tolboom H, Goldschmeding R, Zwaginga JJ, Rabelink TJ, Verhaar MC. Bone-marrow-derived cells contribute to endothelial repair after thrombotic microangiopathy. Blood 99:1095 (2002). [IF 9.060]

Research Support (over the last 10 years)

Total Support>7M€

  1. Ongoing Research Support: NWO/ ZonMw TAS grant (€2,000,000), NWO/ZonMw-VIDI (€600,000), NWO/ZonMw-ASPASIA (€100,000), NWO/ ZonMw TAS grant (€225,000), Netherlands Heart Foundation (€250,000), Vrienden UMCU (€250,000&€100,000); Dutch Kidney Foundation (€260,000&€100,000); CVON 1Valve (€250,000); RM Initiative UMCU/TUe (€375,000); Netherlands Institute for Regenerative Medicine (NIRM) (€560,000); BioMedical Materials Program (BMM) project (iValve)(€280,000).
  2. Completed Research Support: Various: NWO/ZonMw; Dutch Kidney Foundation; Netherlands Heart Foundation; Netherlands Foundation for Cardiovascular Excellence; Strategic Incentive UMCU.